Can a pill tame ulcerative colitis? new trial seeks answers

NCT ID NCT07744646

Not yet recruiting Disease control Sponsor: The First Affiliated Hospital of Anhui Medical University Source: ClinicalTrials.gov ↗

First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental oral medication called Alpha-0261 in about 10 adults with moderate to severe ulcerative colitis. The main goal is to check the drug's safety and tolerability, while also looking at whether it can help reduce symptoms and lead to clinical remission by week 10. Participants will take the tablet and be monitored closely for side effects and changes in their condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Alpha-0261 tablets
What this could lead to: If successful, this could lead to a new oral treatment option for ulcerative colitis, potentially helping more patients achieve remission.
What could go wrong: This is an early-phase trial with only 10 participants, so results may not apply broadly. The drug's safety and effectiveness are still unproven, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS (UC)

Contacts and locations

Locations

The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, 230000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.